×
For best experience we recommend to activate Javascript in your browser.
NUMA1 antibody (AA 1700-2115)
The Mouse Monoclonal anti-NUMA1 antibody has been validated for WB, IHC, IP and ICC. It is suitable to detect NUMA1 in samples from Human.
Quick Overview for NUMA1 antibody (AA 1700-2115) (ABIN7623755)
Target
See all NUMA1 Antibodies
NUMA1
(Nuclear Mitotic Apparatus Protein 1 (NUMA1))
Reactivity
All reactivities for NUMA1 antibodies
Human
Host
All hosts for NUMA1 antibodies
Mouse
Clonality
All clonalities for NUMA1 antibodies
Monoclonal
Conjugate
All conjugates for NUMA1 antibodies
This NUMA1 antibody is un-conjugated
Application
All applications for NUMA1 antibodies
Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
Clone
C4
Product Details anti-NUMA1 Antibody
(hide)
Binding Specificity
All epitopes for NUMA1 antibodies
AA 1700-2115
Purpose
Nuclear Mitotic Apparatus Protein 1 (NUMA1) Monoclonal Antibody
Sequence
Phe1700~His2115
Characteristics
The Nuclear Mitotic Apparatus Protein 1 (NUMA1) Monoclonal Antibody (Species: Human) has been validated for the following applications: WB, IHC, ICC, IP.
Purification
Affinity Chromatography
Isotype
IgG1 kappa
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
1 mg/mL
Buffer
0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.
Expiry Date
12 months
Target Details for NUMA1
(hide)
Target
NUMA1
(Nuclear Mitotic Apparatus Protein 1 (NUMA1))
Alternative Name
NUMA1
Gene ID
4926
UniProt
Q14980
Pathways
Caspase Cascade in Apoptosis , Regulation of Actin Filament Polymerization , M Phase
Recently viewed
(hide)
Chat with us , powered by LiveChat